Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor model based on the published strategy ...

Novo Nordisk (NVO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

Novo Nordisk missed estimates for sales while earnings were in line. Revenues rose 18% at a constant exchange rate (CER), driven mainly by its GLP-1 products. Its GLP-1 sales increased 11% at CER.

Septerna (NASDAQ:SEPN) climbed ~63% in the premarket on Wednesday after the Wegovy maker Novo Nordisk (NVO) agreed to jointly develop and commercialize oral small-molecule drugs for obesity and ...

However, over the long term, investing in top Nasdaq stocks can still make good sense. Year to date, entering trading on Tuesday, the Nasdaq was down more than 8% since the start of the year.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

Google’s logo just got a little bit blurrier. In a new logo quietly rolled out across iOS and Pixel, the search giant ditches its color-blocked “G” for gradients. Google’s new logo keeps ...

Galaxy anticipates listing on the Nasdaq, a tech-focused US stock exchange, by the middle of May, pending approval from the Toronto Stock Exchange, on which the company is already listed ...

As of mid-morning trading, the tech-heavy Nasdaq Composite is on pace for a ... Novo Nordisk (NYSE: NVO), the maker of the weight loss drug Wegovy, fell as much as 5% amid an executive shakeup.